US5362866A
(en)
*
|
1983-09-02 |
1994-11-08 |
Molecular Biosystems, Inc. |
Oligonucleotide polymeric support system with an oxidation cleavable link
|
US4959463A
(en)
*
|
1985-10-15 |
1990-09-25 |
Genentech, Inc. |
Intermediates
|
FR2596761B1
(fr)
*
|
1986-04-08 |
1988-05-20 |
Commissariat Energie Atomique |
Derives de nucleosides et leur utilisation pour la synthese d'oligonucleotides
|
US5204456A
(en)
*
|
1986-04-08 |
1993-04-20 |
Commissariat A L'energie Atomique |
Derivatives of nucleosides and their use for the synthesis of oligonucleotides
|
US4816571A
(en)
*
|
1987-06-04 |
1989-03-28 |
Applied Biosystems, Inc. |
Chemical capping by phosphitylation during oligonucleotide synthesis
|
US6756496B1
(en)
|
1988-09-23 |
2004-06-29 |
Isis Pharmaceuticals, Inc. |
Nucleoside hydrogen phosphonodithioate diesters and activated phosphonodithioate analogues
|
US5194599A
(en)
*
|
1988-09-23 |
1993-03-16 |
Gilead Sciences, Inc. |
Hydrogen phosphonodithioate compositions
|
US5262530A
(en)
|
1988-12-21 |
1993-11-16 |
Applied Biosystems, Inc. |
Automated system for polynucleotide synthesis and purification
|
GB8902689D0
(en)
*
|
1989-02-07 |
1989-03-30 |
Ici Plc |
Assay method
|
US5149798A
(en)
*
|
1989-04-06 |
1992-09-22 |
Worcester Foundation For Experimental Biology |
Process for synthesizing oligonucleotides and their analogs adaptable to large scale syntheses
|
US5256775A
(en)
*
|
1989-06-05 |
1993-10-26 |
Gilead Sciences, Inc. |
Exonuclease-resistant oligonucleotides
|
US6300486B1
(en)
*
|
1989-06-15 |
2001-10-09 |
Isis Pharmaceuticals, Inc. |
Large scale synthesis of oligonucleotides and their associated analogs
|
US5204455A
(en)
*
|
1989-06-15 |
1993-04-20 |
Froehler Brian C |
Monomethoxytrityl protected oligonucleotides bound to a solid support
|
US5164491A
(en)
*
|
1989-06-15 |
1992-11-17 |
Gilead Sciences |
Large scale synthesis of oligonucleotides and their associated analogs
|
EP0450060A1
(de)
*
|
1989-10-26 |
1991-10-09 |
Sri International |
Dns-sequenzierung
|
US7037646B1
(en)
|
1990-01-11 |
2006-05-02 |
Isis Pharmaceuticals, Inc. |
Amine-derivatized nucleosides and oligonucleosides
|
US5321131A
(en)
*
|
1990-03-08 |
1994-06-14 |
Hybridon, Inc. |
Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
|
US5166195A
(en)
*
|
1990-05-11 |
1992-11-24 |
Isis Pharmaceuticals, Inc. |
Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
|
US5214134A
(en)
*
|
1990-09-12 |
1993-05-25 |
Sterling Winthrop Inc. |
Process of linking nucleosides with a siloxane bridge
|
US5432272A
(en)
*
|
1990-10-09 |
1995-07-11 |
Benner; Steven A. |
Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
|
US5594121A
(en)
*
|
1991-11-07 |
1997-01-14 |
Gilead Sciences, Inc. |
Enhanced triple-helix and double-helix formation with oligomers containing modified purines
|
US5734020A
(en)
*
|
1991-11-20 |
1998-03-31 |
Cpg, Inc. |
Production and use of magnetic porous inorganic materials
|
US5610274A
(en)
*
|
1991-11-20 |
1997-03-11 |
Cpg, Inc. |
Production and use of magnetic porous inorganic materials
|
US6235887B1
(en)
*
|
1991-11-26 |
2001-05-22 |
Isis Pharmaceuticals, Inc. |
Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
|
TW393513B
(en)
*
|
1991-11-26 |
2000-06-11 |
Isis Pharmaceuticals Inc |
Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
|
ATE226093T1
(de)
*
|
1991-11-26 |
2002-11-15 |
Isis Pharmaceuticals Inc |
Gesteigerte bildung von triple- und doppelhelices aus oligomeren mit modifizierten pyrimidinen
|
AU3250093A
(en)
|
1991-12-12 |
1993-07-19 |
Gilead Sciences, Inc. |
Nuclease stable and binding competent oligomers and methods for their use
|
US5817781A
(en)
|
1992-06-01 |
1998-10-06 |
Gilead Sciences, Inc. |
Modified internucleoside linkages (II)
|
US5583211A
(en)
*
|
1992-10-29 |
1996-12-10 |
Beckman Instruments, Inc. |
Surface activated organic polymers useful for location - specific attachment of nucleic acids, peptides, proteins and oligosaccharides
|
US6087491A
(en)
*
|
1993-01-08 |
2000-07-11 |
Hybridon, Inc. |
Extremely high purity oligonucleotides and methods of synthesizing them using dimer blocks
|
JPH08507752A
(ja)
*
|
1993-01-08 |
1996-08-20 |
ハイブライドン インコーポレイテッド |
二量体ブロックの合成と二量体ブロックを使ったオリゴヌクレオチド結合法
|
US5476925A
(en)
*
|
1993-02-01 |
1995-12-19 |
Northwestern University |
Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
|
EP0705335A1
(de)
*
|
1993-06-23 |
1996-04-10 |
Genesys Pharma Inc. |
Antisense oligonukleotide und ihre verwendung bei der infektion mit menschlichem immunschwächevirus
|
US6653458B1
(en)
|
1993-09-03 |
2003-11-25 |
Isis Pharmaceuticals, Inc. |
Modified oligonucleotides
|
FR2714061B1
(fr)
*
|
1993-12-16 |
1996-03-08 |
Genset Sa |
Procédé de préparation de polynucléotides sur support solide et appareil permettant sa mise en Óoeuvre.
|
US5637684A
(en)
*
|
1994-02-23 |
1997-06-10 |
Isis Pharmaceuticals, Inc. |
Phosphoramidate and phosphorothioamidate oligomeric compounds
|
US5623068A
(en)
*
|
1994-03-07 |
1997-04-22 |
Beckman Instruments, Inc. |
Synthesis of DNA using substituted phenylacetyl-protected nucleotides
|
US6639061B1
(en)
|
1999-07-07 |
2003-10-28 |
Isis Pharmaceuticals, Inc. |
C3′-methylene hydrogen phosphonate oligomers and related compounds
|
US5514789A
(en)
*
|
1994-04-21 |
1996-05-07 |
Barrskogen, Inc. |
Recovery of oligonucleotides by gas phase cleavage
|
US6214987B1
(en)
|
1994-09-02 |
2001-04-10 |
Andrew C. Hiatt |
Compositions for enzyme catalyzed template-independent formation of phosphodiester bonds using protected nucleotides
|
US5872244A
(en)
*
|
1994-09-02 |
1999-02-16 |
Andrew C. Hiatt |
3' protected nucleotides for enzyme catalyzed template-independent creation of phosphodiester bonds
|
US5808045A
(en)
*
|
1994-09-02 |
1998-09-15 |
Andrew C. Hiatt |
Compositions for enzyme catalyzed template-independent creation of phosphodiester bonds using protected nucleotides
|
US6232465B1
(en)
|
1994-09-02 |
2001-05-15 |
Andrew C. Hiatt |
Compositions for enzyme catalyzed template-independent creation of phosphodiester bonds using protected nucleotides
|
US5763594A
(en)
*
|
1994-09-02 |
1998-06-09 |
Andrew C. Hiatt |
3' protected nucleotides for enzyme catalyzed template-independent creation of phosphodiester bonds
|
US5990300A
(en)
*
|
1994-09-02 |
1999-11-23 |
Andrew C. Hiatt |
Enzyme catalyzed template-independent creation of phosphodiester bonds using protected nucleotides
|
US5639875A
(en)
*
|
1995-02-01 |
1997-06-17 |
Hybridon, Inc. |
Methods for H-phosphonate syntheis of oligonucleotides using triphosgene
|
US5683875A
(en)
*
|
1995-05-04 |
1997-11-04 |
Hewlett-Packard Company |
Method for detecting a target nucleic acid analyte in a sample
|
US5955599A
(en)
*
|
1995-06-01 |
1999-09-21 |
Hybridon, Inc. |
Process for making oligonucleotides containing o- and s- methylphosphotriester internucleoside linkages
|
US6531589B1
(en)
|
1995-06-01 |
2003-03-11 |
Hybridon, Inc. |
Base protecting groups and synthons for oligonucleotide synthesis
|
US5962674A
(en)
*
|
1995-06-01 |
1999-10-05 |
Hybridon, Inc. |
Synthesis of oligonucleotides containing alkylphosphonate internucleoside linkages
|
WO1996039414A1
(en)
*
|
1995-06-01 |
1996-12-12 |
Hybridon, Inc. |
Novel base protecting groups for oligonucleotide synthesis
|
US6140482A
(en)
*
|
1995-06-01 |
2000-10-31 |
Hybridon, Inc. |
Primary phosphoramidate internucleoside linkages and oligonucleotides containing the same
|
US5856464A
(en)
*
|
1995-06-07 |
1999-01-05 |
Lajolla Pharmaceutical Company |
Selective capping solution phase oligonucleotide synthesis
|
WO1997014706A1
(en)
|
1995-10-19 |
1997-04-24 |
Nexstar Pharmaceuticals, Inc. |
Method for solution phase synthesis of oligonucleotides
|
US5705629A
(en)
*
|
1995-10-20 |
1998-01-06 |
Hybridon, Inc. |
Methods for H-phosphonate synthesis of mono- and oligonucleotides
|
WO1998017675A1
(en)
*
|
1996-10-18 |
1998-04-30 |
Hybridon, Inc. |
Improved methods for h-phosphonate synthesis of mono- and oligonucleotides
|
US5902881A
(en)
*
|
1997-03-03 |
1999-05-11 |
Isis Pharmaceuticals, Inc. |
Reagent useful for synthesizing sulfurized oligonucleotide analogs
|
US5760209A
(en)
*
|
1997-03-03 |
1998-06-02 |
Isis Pharmaceuticals, Inc. |
Protecting group for synthesizing oligonucleotide analogs
|
ES2131463B1
(es)
|
1997-04-08 |
2000-03-01 |
Lilly Sa |
Derivados de ciclopropilglicina con propiedades farmaceuticas.
|
US6242591B1
(en)
*
|
1997-10-15 |
2001-06-05 |
Isis Pharmaceuticals, Inc. |
Synthesis of sulfurized 2'-substituted oligonucleotides
|
US6114519A
(en)
*
|
1997-10-15 |
2000-09-05 |
Isis Pharmaceuticals, Inc. |
Synthesis of sulfurized oligonucleotides
|
US6441150B1
(en)
*
|
1997-12-16 |
2002-08-27 |
Isis Pharmaceuticals, Inc. |
Compounds for the Synthesis of Nucleotide or oligonucleotide phosphoramidites
|
US7273933B1
(en)
*
|
1998-02-26 |
2007-09-25 |
Isis Pharmaceuticals, Inc. |
Methods for synthesis of oligonucleotides
|
US6207819B1
(en)
|
1999-02-12 |
2001-03-27 |
Isis Pharmaceuticals, Inc. |
Compounds, processes and intermediates for synthesis of mixed backbone oligomeric compounds
|
CA2370478A1
(en)
|
1999-03-24 |
2000-09-28 |
Serge L. Beaucage |
N-acylphosphoramidites and their use in oligonucleotide synthesis
|
US6932943B1
(en)
|
2001-01-26 |
2005-08-23 |
Third Wave Technologies |
Nucleic acid synthesizers
|
US20030072689A1
(en)
*
|
2001-08-15 |
2003-04-17 |
Third Wave Technologies, Inc. |
Polymer synthesizer
|
US7435390B2
(en)
*
|
2001-01-26 |
2008-10-14 |
Third Wave Technologies, Inc. |
Nucleic acid synthesizers
|
US20080261220A1
(en)
*
|
2000-11-30 |
2008-10-23 |
Third Wave Technologies, Inc. |
Nucleic Acid Detection Assays
|
AU2002220870A1
(en)
*
|
2000-12-05 |
2002-06-18 |
Avecia Limited |
Process for the preparation of phosphorothionate oligonucleotides
|
WO2002081476A1
(en)
*
|
2001-04-06 |
2002-10-17 |
Micrologix Biotech, Inc. |
Thiophosphate nucleic acid-based compounds
|
AU2002353001A1
(en)
|
2001-12-03 |
2003-06-17 |
The Government Of The United States Of America, Represented By The Secretary Of The Department Of He |
Thermolabile hydroxyl protecting groups and methods of use
|
US20060009409A1
(en)
|
2002-02-01 |
2006-01-12 |
Woolf Tod M |
Double-stranded oligonucleotides
|
EP3415625A1
(de)
|
2002-02-01 |
2018-12-19 |
Life Technologies Corporation |
Doppelsträngige oligonukleotide
|
US20030166282A1
(en)
|
2002-02-01 |
2003-09-04 |
David Brown |
High potency siRNAS for reducing the expression of target genes
|
US20050009051A1
(en)
*
|
2002-09-27 |
2005-01-13 |
Board Of Regents, The University Of Texas |
Diagnosis of mould infection
|
EP1638587A4
(de)
|
2003-02-14 |
2007-04-18 |
Univ Missouri |
Empfängnisverhütende verfahren und zusammensetzungen betreffend proteasomale störung
|
JP2007526772A
(ja)
*
|
2004-02-27 |
2007-09-20 |
プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ |
インサイチュー配列決定用ポロニー蛍光ビーズ
|
EP2290071B1
(de)
|
2004-05-28 |
2014-12-31 |
Asuragen, Inc. |
Verfahren und Zusammensetzungen mit MicroRNA
|
DE602005021525D1
(de)
|
2004-09-14 |
2010-07-08 |
Univ Colorado |
R behandlung mit bucindolol
|
WO2006137941A2
(en)
|
2004-11-12 |
2006-12-28 |
Ambion, Inc. |
Methods and compositions involving mirna and mirna inhibitor molecules
|
WO2006065751A2
(en)
|
2004-12-13 |
2006-06-22 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Cpg oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
|
EP1871913A2
(de)
*
|
2005-03-25 |
2008-01-02 |
Ambion, Inc. |
Verfahren und zusammensetzungen zur verringerung abundanter rna-transkripte
|
US20090131348A1
(en)
|
2006-09-19 |
2009-05-21 |
Emmanuel Labourier |
Micrornas differentially expressed in pancreatic diseases and uses thereof
|
AU2007333109A1
(en)
|
2006-12-08 |
2008-06-19 |
Asuragen, Inc. |
Functions and targets of let-7 micro RNAs
|
US9605035B2
(en)
|
2008-01-10 |
2017-03-28 |
Research Development Foundation |
Vaccines and diagnostics for the ehrlichioses
|
PL2245464T3
(pl)
|
2008-01-25 |
2017-08-31 |
Multivir Inc. |
Biomarkery p53
|
EP2990487A1
(de)
|
2008-05-08 |
2016-03-02 |
Asuragen, INC. |
Zusammensetzungen und verfahren in zusammenhang mit der mirna-modulation von neovaskularisation oder angiogenese
|
US20100047876A1
(en)
*
|
2008-08-08 |
2010-02-25 |
President And Fellows Of Harvard College |
Hierarchical assembly of polynucleotides
|
US20100135904A1
(en)
|
2008-11-07 |
2010-06-03 |
Research Development Foundation |
Compositions and methods for the inhibition of cripto / grp78 complex formation and signaling
|
US9084781B2
(en)
|
2008-12-10 |
2015-07-21 |
Novartis Ag |
MEK mutations conferring resistance to MEK inhibitors
|
EP2379720B1
(de)
|
2009-01-20 |
2016-08-17 |
Alona Zilberberg |
Durch den promoter mir-21 angetriebene gezielte krebstherapie
|
US20110045080A1
(en)
*
|
2009-03-24 |
2011-02-24 |
William Marsh Rice University |
Single-Walled Carbon Nanotube/Bioactive Substance Complexes and Methods Related Thereto
|
JP5785942B2
(ja)
|
2009-06-29 |
2015-09-30 |
ルミネックス コーポレーション |
ヘアピンコンフォメーションを有するキメラプライマーおよびその使用法
|
EP2470560B1
(de)
|
2009-08-28 |
2015-06-10 |
Research Development Foundation |
Urocortin-2-analoga und ihre verwendung
|
US9512481B2
(en)
|
2009-09-11 |
2016-12-06 |
The Regents Of The University Of Colorado, A Body Corporate |
Polymorphisms in the PDE3A gene
|
EP2515899B1
(de)
|
2009-12-23 |
2016-05-25 |
ARCA biopharma, Inc. |
Verfahren und zusammensetzungen für herz-kreislauf-erkrankungen und -leiden
|
EP2535411A4
(de)
|
2010-02-12 |
2013-07-03 |
M & D Inc |
Sonde für die diagnose von hpv-genotypen und analyseverfahren dafür
|
WO2011106298A1
(en)
|
2010-02-25 |
2011-09-01 |
Dana-Farber Cancer Institute, Inc. |
Braf mutations conferring resistance to braf inhibitors
|
ES2631458T3
(es)
|
2010-03-04 |
2017-08-31 |
Interna Technologies B.V. |
Molécula de ARNmi definida por su fuente y sus usos terapéuticos en el cáncer asociado a la EMT
|
US20130131148A1
(en)
|
2010-04-12 |
2013-05-23 |
Noam Shomron |
Micro-rna for cancer diagnosis, prognosis and therapy
|
JP5908466B2
(ja)
|
2010-06-09 |
2016-04-26 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
Raf及びmek阻害剤に対する耐性を与えるmek1変異
|
NZ719520A
(en)
|
2010-07-06 |
2017-07-28 |
Int Tech Bv |
Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
|
WO2012048341A1
(en)
|
2010-10-08 |
2012-04-12 |
President And Fellows Of Harvard College |
High-throughput single cell barcoding
|
EP2640851A2
(de)
|
2010-11-17 |
2013-09-25 |
Asuragen, Inc. |
Mirna als biomarker zur unterscheidung zwischen benignen und malignen neoplasien der schilddrüse
|
EP2474617A1
(de)
|
2011-01-11 |
2012-07-11 |
InteRNA Technologies BV |
MIR zur Behandlung von Neoangiogenese
|
SG192252A1
(en)
|
2011-02-03 |
2013-09-30 |
Mirna Therapeutics Inc |
Synthetic mimics of mir-34
|
CN103459598B
(zh)
|
2011-02-03 |
2016-08-10 |
米尔纳医疗股份有限公司 |
Mir-124的合成模拟物
|
WO2013040251A2
(en)
|
2011-09-13 |
2013-03-21 |
Asurgen, Inc. |
Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
|
CA2844577A1
(en)
|
2011-09-13 |
2013-03-21 |
Ottawa Hospital Research Institute |
Microrna inhibitors
|
EP2766498B1
(de)
|
2011-10-14 |
2019-06-19 |
President and Fellows of Harvard College |
Sequenzierung durch strukturanordnung
|
WO2013063519A1
(en)
|
2011-10-26 |
2013-05-02 |
Asuragen, Inc. |
Methods and compositions involving mirna expression levels for distinguishing pancreatic cysts
|
EP3369818B1
(de)
|
2011-12-22 |
2021-06-09 |
InteRNA Technologies B.V. |
Mirna zur behandlung von kopf-hals-karzinom
|
US9914967B2
(en)
|
2012-06-05 |
2018-03-13 |
President And Fellows Of Harvard College |
Spatial sequencing of nucleic acids using DNA origami probes
|
CN104662544B
(zh)
|
2012-07-19 |
2018-08-03 |
哈佛大学校长及研究员协会 |
利用核酸存储信息的方法
|
US9993522B2
(en)
|
2012-09-18 |
2018-06-12 |
Uti Limited Partnership |
Treatment of pain by inhibition of USP5 de-ubiquitinase
|
US20140100124A1
(en)
|
2012-10-04 |
2014-04-10 |
Asuragen, Inc. |
Diagnostic mirnas for differential diagnosis of incidental pancreatic cystic lesions
|
US9476089B2
(en)
|
2012-10-18 |
2016-10-25 |
President And Fellows Of Harvard College |
Methods of making oligonucleotide probes
|
EP2917348A1
(de)
|
2012-11-06 |
2015-09-16 |
InteRNA Technologies B.V. |
Kombination zur behandlung von erkrankungen oder zuständen im zusammenhang mit melanom oder behandlung von erkrankungen und zuständen im zusammenhang mit aktivierten b-raf-signalweg
|
US10125373B2
(en)
|
2013-01-22 |
2018-11-13 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Geminiviral vector for expression of rituximab
|
WO2014134179A1
(en)
|
2013-02-28 |
2014-09-04 |
The Board Of Regents Of The University Of Texas System |
Methods for classifying a cancer as susceptible to tmepai-directed therapies and treating such cancers
|
EP3578666A1
(de)
|
2013-03-12 |
2019-12-11 |
President and Fellows of Harvard College |
Verfahren zur erzeugung einer dreidimensionalen nukleinsäure mit matrix
|
EP3404116B1
(de)
|
2013-03-15 |
2022-10-19 |
The University of Chicago |
Verfahren und zusammensetzungen in zusammenhang mit t-zell aktivität
|
EP3065706A4
(de)
|
2013-11-08 |
2017-11-29 |
Baylor Research Institute |
Nukleare lokalisierung von glp-1 zur stimulation der herzmuskelregenerierung und reversion von herzversagen
|
EP3259346A4
(de)
|
2015-02-20 |
2018-07-11 |
Baylor College of Medicine |
P63-inaktivierung zur behandlung von herzinsuffizienz
|
CA3019635A1
(en)
|
2016-03-31 |
2017-10-05 |
Baylor Research Institute |
Angiopoietin-like protein 8 (angptl8)
|
US10927379B2
(en)
|
2016-09-16 |
2021-02-23 |
Bio-Path Holdings, Inc. |
Combination therapy with liposomal antisense oligonucleotides
|
CA3079524A1
(en)
|
2017-11-03 |
2019-05-09 |
Interna Technologies B.V. |
Mirna molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation
|
MX2020012717A
(es)
|
2018-05-25 |
2021-07-15 |
Arca Biopharma Inc |
Métodos y composiciones con bucindolol para el tratamiento de la fibrilación auricular.
|
IL302594A
(en)
|
2020-11-09 |
2023-07-01 |
1E Therapeutics Ltd |
Methods based on catalytic sequences for the treatment or prevention of bacterial infections
|
KR20230126725A
(ko)
|
2020-12-28 |
2023-08-30 |
1이 테라퓨틱스 엘티디. |
침묵화를 위한 P21 mRNA 표적 부위
|
AU2021416356A1
(en)
|
2020-12-28 |
2023-08-10 |
1E Therapeutics, Ltd. |
P21 mrna targeting dnazymes
|
WO2022217283A1
(en)
|
2021-04-08 |
2022-10-13 |
Joslin Diabetes Center, Inc. |
Methods of diagnosing and predicting renal decline
|
WO2024015766A1
(en)
|
2022-07-12 |
2024-01-18 |
Topogene Inc. |
Scalable, submicron-resolution replication of dna arrays
|